[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]

Area of Science:

• Oncology
• Pharmacology
• Biomarkers

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are established treatments for advanced non-small cell lung cancer (NSCLC).
• Significant questions persist regarding the optimal application and integration of anti-EGFR therapies in NSCLC management.
• While predictive biomarkers for EGFR-targeted therapies exist, their real-world clinical utility requires further validation.

Purpose of the Study:

• To address unresolved clinical questions surrounding the use of EGFR TKIs in advanced NSCLC.
• To explore the clinical utility of biological factors in predicting response to EGFR-targeted therapies.
• To investigate optimal strategies for combining EGFR inhibitors with chemotherapy, novel agents, and loco-regional treatments in earlier NSCLC stages.

Main Methods:

• Review of current literature and clinical practice guidelines on EGFR TKI use in NSCLC.
• Analysis of reported biological factors associated with EGFR inhibitor response.
• Discussion of ongoing and future clinical trials evaluating combination therapies and earlier stage applications.

Main Results:

• The clinical utility of identified biological factors for routine practice selection of patients for EGFR-targeted therapies remains undetermined.
• Optimal combination strategies for EGFR inhibitors with chemotherapy, new biological agents, or loco-regional therapies in earlier NSCLC stages are still under investigation.
• Current evidence highlights the need for further research to refine the application of EGFR inhibitors.

Conclusions:

• Further clinical trials are essential to establish the precise role and optimal utilization of EGFR TKIs in NSCLC.
• Clarification is needed on how to best integrate EGFR-targeted therapies with other treatment modalities across different disease stages.
• Results from ongoing and future studies will guide the appropriate use of this important class of agents in NSCLC patients.